The risk of developing hepatitis B virus (HBV) related liver disease in isolated anti-HBc carriers1 undergoing chemo or chemo-immunotherapy for non-Hodgkin’s lymphoma is not well known. The use of rituximab has been reported to cause even fatal HBV-related liver disease in this category of patients.2–5
In an attempt to solve this problem, we retrospectively analyzed 1,087 patients with non-Hodgkin’s lymphoma seen from January 1989 through June 2006. Since then, in our Unit, all newly diagnosed patients undergo measurement of HBsAg, anti-HBs, anti-HBc, HBeAg, and antiHBe.
Patients were monitored by liver function tests during and after therapy as follows; on day 1 and day 14 of each cycle, every month for the first six months after completion of chemotherapy, then every 3–4 months for 24 months, and thereafter twice a year.
When a patient developed liver disease (defined as ≥ three-fold increase in alanine aminotransferase [AST] from baseline exceeding the upper limit of normal [>45 IU/L ] or an absolute increase of ALT to more than 100 IU/L)6 we investigated HBsAg. Liver disease attributable to HBV in potential occult carriers was defined as the re-emergence of HBsAg in HBsAg negative/ anti-HBc positive subjects (reverse seroconversion).1
Cheson’s criteria were used to define the response to lymphoma treatment.7
Non-parametric data are expressed with median (range). For parametric groups, the χ test was used to compare the two groups. The risk of HBV related liver disease was calculated using the Kaplan-Meier method.8 The retrospective observational protocol study was approved by the Institutional Review Board.
Of 1,087 non-Hodgkin’s lymphoma patients, 55 (5%) were overt HBV carriers, 394 (36%) were isolated anti- HBc positive, while 638 (58%) showed negative HBV markers or only anti-HBs antibodies. We focused on the 394 potential occult carriers: 200 males, 194 females, median age 62 years (range 34–80). The main lymphoma diagnosis was diffuse large B-cell lymphoma (n=185, 47%).
Of the 394 anti-HBc positive patients, 245 (62%) received chemotherapy and 74 (19%) had immuno-chemotherapy with anti-CD20 monoclonal antibody. Twenty-nine (7%) received other treatment (radiotherapy, interferon, antibiotics etc.) and 46 (12%) did not receive therapy (watch and wait) (Table 1).
Of the patients who received chemo±immuno therapy, 225 were treated with a single line of therapy, 59 with 2 lines of therapy and 64 with more than 2 lines of therapy.
Four of the 394 patients (1%) developed HBV-related liver disease: 2 out of 245 (0.8%) patients treated with chemotherapy only and 2 out of 74 (2.7%) treated with immuno-chemotherapy (p<0.05). No HBV-related liver disease occurred in patients who were simply monitored or in those treated with other therapies. The one year Kaplan-Meier8 risk of HBV-related liver disease in patients treated with immuno-chemotherapy was 3%.
Three out of four events occurred as a consequence of the first line of therapy; one event occurred as a consequence of the third line of therapy.
HBV-related liver disease occurred five months after discontinuation of cytotoxic therapy in 3 cases while in the other patient it occurred during immuno-chemotherapy, disrupting the chemotherapy schedule.
Two out of 4 patients were treated with lamivudine for hepatitis. The other 2 patients received only support treatment (pre-lamivudine era). Transaminase and bilirubin peaks were respectively 9 and 5 times the upper limit of normal in patients treated with Lamivudine, and 37 and 7 times the upper limit of normal in patients treated with support therapy.
All of the 4 patients obtained clinical remission of hepatitis with long-lasting persistence of HBsAg.
Two out of 4 patients obtained complete remission of the lymphoma, even though one of them relapsed and required further therapy. The other 2 patients died with progressive disease.
At present, with the increase in immunosuppressive therapy, the problem of HBV reactivation has become more common. A few cases of even lethal reverse seroconversion in isolated anti-core carriers have been reported after the use of rituximab.2–5,9 However, there is clear evidence of the advantage of using rituximab.10 The risk of rituximab induced HBV-related liver disease must be assessed.
In our center, complete assessment of HBV status has been routine clinical practice in all new lymphoma patients since 1989. Therefore, a retrospective analysis in a uniform population is feasible. One third of Lymphoma patients had isolated anti hepatitis B core positivity.
Our incidence of HBV-related liver disease (2.7%) was significantly greater in the anti-CD20 antibody group. Our results are limited by the fact that retrospective analyses can underestimate the events, particularly after one year post-therapy. Furthermore, none of these patients were on long-term maintenance therapy with rituximab. Larger, multicenter prospective observational trials are necessary to address this issue. A potential occult HBV carrier (i.e. isolated antiHbc) must be treated with the best clinical therapy available even including monoclonal antibodies. While a policy of prophylaxis remains controversial, close monitoring is mandatory.
Acknowledgments
authors wish to thank Stanley L. Schrier for critical reading and suggestions
References
- Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digest Liver Dis. 2007; 39:397-408. Google Scholar
- Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001; 344:68-9. Google Scholar
- Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal hepatitis B virus reactivation post-chemotherapy in a hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendation. Leuk Lymphoma. 2005; 46:1085-9. Google Scholar
- Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meiliche M, Schäfer JH, Zidek W. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003; 102:1930. Google Scholar
- Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y. Anti-HBs positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006; 45:721-4. Google Scholar
- Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62:299-307. Google Scholar
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas. J Clin Oncol. 1999; 17:1244-53. Google Scholar
- Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-81. Google Scholar
- Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005; 11:189-91. Google Scholar
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346:235-42. Google Scholar